Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.29 | N/A | +12.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.29 | N/A | +12.08% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in their product pipeline and ongoing R&D efforts. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in research and development.
There was an emphasis on maintaining a strong pipeline of products.
Amgen's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 0.25%. This could suggest that investors were looking for more comprehensive revenue details or future guidance, which were not provided.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IDEXX LABS INC
Jul 24, 2009